In contrast, data on the mechanisms of action of IFN-β in vivo are abundant in MS [96-98], with IFN-β therapy effectively upregulating CD86 in monocytes and B cells [33,34,89,99] while downregulating CD80 in vivo[49] but not in vitro[33]. The gene discussed is IFNB1; the disease is myeloid sarcoma.